Virtus LifeSci Biotech Clinical Trials ETF Rating $54.20 +1.40 (+2.65%) As of 07/7/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatingsBuy This Stock Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.75Holdings in BBC have an aggregate rating of Moderate Buy based on 293 analyst ratings issued in the past year covering 25 companies (23.0% of the portfolio).BBC Aggregate Price Target$54.20High Prediction$54.20Average Prediction$54.20Low Prediction$54.20Holdings in BBC have an aggregate price target of $54.20 and a range of $54.20 to $54.20 covering 25 companies (23.0% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.23%SLSSELLAS Life Sciences Group$13.50-3.2%0.394 of 5 stars2.33$10.00 -25.9%3Analyst Forecast1.17%DFTXDefinium Therapeutics$44.48+0.3%1.8656 of 5 stars3.00$46.92 5.5%171.11%RGNXREGENXBIO$15.02+1.3%3.3725 of 5 stars2.75$23.82 58.6%121.07%QUREuniQure$41.41+0.1%3.5309 of 5 stars2.65$64.17 55.0%17Insider Trade0.99%MNPRMonopar Therapeutics$95.22-2.0%1.6115 of 5 stars3.00$108.75 14.2%130.97%ABCLAbCellera Biologics$7.69-2.3%2.0121 of 5 stars2.71$8.33 8.4%7News CoverageAnalyst UpgradeGap Up0.95%MBXMBX Biosciences$62.00+7.5%0.6762 of 5 stars2.77$60.22 -2.9%130.94%APGEApogee Therapeutics$133.54+0.0%1.1205 of 5 stars2.24$121.25 -9.2%210.91%FDMT4D Molecular Therapeutics$12.82+0.8%1.739 of 5 stars2.67$29.88 133.0%90.90%JBIOJade Biosciences$22.45+5.4%2.944 of 5 stars2.90$47.13 109.9%100.89%PVLAPalvella Therapeutics$145.70+3.8%2.796 of 5 stars2.94$199.53 36.9%160.88%NRIXNurix Therapeutics$24.40+1.5%3.1525 of 5 stars2.81$32.20 32.0%16Upcoming Earnings0.86%LXRXLexicon Pharmaceuticals$2.37+2.2%2.5114 of 5 stars2.75$4.55 92.0%4Positive News0.86%BIOABioAge Labs$24.40-1.8%2.7412 of 5 stars2.71$43.50 78.3%70.86%AKTSAktis Oncology$27.58+3.8%1.4726 of 5 stars2.88$34.00 23.3%8Lockup Expiration0.86%VKTXViking Therapeutics$42.13+8.8%2.5922 of 5 stars2.79$93.60 122.2%140.85%ATAIAtai Beckley$5.19+4.6%3.6854 of 5 stars2.92$15.50 198.7%12News CoverageAnalyst Forecast0.85%GENBGenerate Biomedicines$16.22-4.1%2.0574 of 5 stars2.86$25.40 56.6%70.85%NTLAIntellia Therapeutics$17.43-2.3%2.4741 of 5 stars2.35$20.46 17.4%23News Coverage0.84%PRMEPrime Medicine$3.992.8877 of 5 stars2.86$7.53 88.8%70.84%CGEMCullinan Therapeutics$18.16+2.0%2.2574 of 5 stars2.63$32.00 76.2%8Insider Trade0.84%GHRSGH Research$26.89+2.8%2.7856 of 5 stars2.73$40.38 50.1%110.84%BCAXBicara Therapeutics$30.40+4.0%0.5369 of 5 stars2.73$30.27 -0.4%150.83%RLAYRelay Therapeutics$19.74+4.4%2.2393 of 5 stars3.00$23.30 18.0%110.83%SLDBSolid Biosciences$11.15+0.7%3.0149 of 5 stars2.92$17.00 52.5%12News Coverage This page (NYSEARCA:BBC) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: “This Could Be Bigger Than Nvidia”Fox News contributor Louis Navellier recently sat down to reveal details on Elon Musk's little-known AI projec...InvestorPlace | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
